Swati Singh

Ms. Swati Singh

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2023 in Bioengineering
Verified
Journal Article
Open access
PDF file
HTHarshita Tiwari
Harshita Tiwari
NRNilesh Rai
Nilesh Rai
SSSwati Singh
Swati Singh
Priyamvada GuptaPriyamvada Gupta
Priyamvada Gupta
Ashish VermaAshish Verma
Ashish Verma
Vibhav GautamVibhav Gautam
Vibhav Gautam
Nano-oncology is a branch of biomedical research and engineering that focuses on using nanotechnology in cancer diagnosis and treatment. Nanomaterials are extensively employed in the field of oncology because of their minute size and ultra-specificity. A wide range of nanocarriers, such as dendrimers, micelles, PEGylated liposomes, and polymeric nanoparticles are used to facilitate the efficient transport of anti-cancer drugs at the target tumor site. Real-time labeling and monitoring of cancer cells using quantum dots is essential for determining the level of therapy needed for treatment. The drug is targeted to the tumor site either by passive or active means. Passive targeting makes use of the tumor microenvironment and enhanced permeability and retention effect, while active targeting involves the use of ligand-coated nanoparticles. Nanotechnology is being used to diagnose the early stage of cancer by detecting cancer-specific biomarkers using tumor imaging. The implication of nanotechnology in cancer therapy employs photoinduced nanosensitizers, reverse multidrug resistance, and enabling efficient delivery of CRISPR/Cas9 and RNA molecules for therapeutic applications. However, despite recent advancements in nano-oncology, there is a need to delve deeper into the domain of designing and applying nanoparticles for improved cancer diagnostics.

13 March 2024 in ACS Chemical Health & Safety
Verified
Journal Article
Closed access
HTHarshita Tiwari
Harshita Tiwari
Priyamvada GuptaPriyamvada Gupta
Priyamvada Gupta
Ashish VermaAshish Verma
Ashish Verma
SSSwati Singh
Swati Singh
RKRajiv Kumar
Rajiv Kumar
Vibhav GautamVibhav Gautam
Vibhav Gautam

8 August 2023 in Mycology
Verified
Journal Article
Open access
Ashish VermaAshish Verma
Ashish Verma
HTHarshita Tiwari
Harshita Tiwari
SSSwati Singh
Swati Singh
Priyamvada GuptaPriyamvada Gupta
Priyamvada Gupta
NRNilesh Rai
Nilesh Rai
Vibhav GautamVibhav Gautam
Vibhav Gautam
Fungal endophytes have emerged as a promising source of secondary metabolites with significant potential for various applications in the field of biomedicine. The biosynthetic gene clusters of endophytic fungi are responsible for encoding several enzymes and transcriptional factors that are involved in the biosynthesis of secondary metabolites. The investigation of fungal metabolic potential at genetic level faces certain challenges, including the synthesis of appropriate amounts of chemicals, and loss of the ability of fungal endophytes to produce secondary metabolites in an artificial culture medium. Therefore, there is a need to delve deeper into the field of fungal genomics and transcriptomics to explore the potential of fungal endophytes in generating secondary metabolites governed by biosynthetic gene clusters. The silent biosynthetic gene clusters can be activated by modulating the chromatin structure using chemical compounds. Epigenetic modification plays a significant role by inducing cryptic gene responsible for the production of secondary metabolites using DNA methyl transferase and histone deacetylase. CRISPR-Cas9-based genome editing emerges an effective tool to enhance the production of desired metabolites by modulating gene expression. This review primarily focuses on the significance of epigenetic elicitors and their capacity to boost the production of secondary metabolites from endophytes. This article holds the potential to rejuvenate the drug discovery pipeline by introducing new chemical compounds.

18 August 2025 in Nanoscale Advances
Verified
Journal Article
Open access
PDF file
HTHarshita Tiwari
Harshita Tiwari
SSSwati Singh
Swati Singh
RKRajiv Kumar
Rajiv Kumar
AMAbhijit Mandal
Abhijit Mandal
APAbhishek Pathak
Abhishek Pathak
Vibhav GautamVibhav Gautam
Vibhav Gautam
Schematic illustration of theranostic nanoparticle (NP)-based contrast agents for multimodal imaging, depicting major NP categories used across different imaging modalities and disease-specific theranostics.

20 December 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
NCNayanika Chakraborty
Nayanika Chakraborty
IRIndrajit Roy
Indrajit Roy
PKPradeep Kumar
Pradeep Kumar
SSSwati Singh
Swati Singh
Rajiv PathakRajiv Pathak
Rajiv Pathak
HGHemant Kumar Gautam
Hemant Kumar Gautam
Prussian blue nanoparticles (PBNPs) have gained significant attraction in the field of nanomedicine due to their excellent biocompatibility, potential for nanoscale production, exceptional photothermal conversion ability, and multi-enzyme mimicking capabilities. PBNPs have made considerable advancements in their application to biomedical fields. This review embarks with a comprehensive understanding of the physicochemical properties and chemical profiling of PB-based nanoparticles, discussing systematic approaches to tune their dimensions, shapes, and sizes, as well as their biomedical properties. Subsequently, the use of PB-based NPs in the biomedical sector is extensively discussed and categorized based on the various features of modified PBNPs, either in combination with drugs or their analogues. Finally, the article highlights the existing challenges associated with current studies and explores the latest developments in these rapidly evolving PB-based nanoplatforms and their therapeutic potentials. Overall, this review aims to deepen the understanding of PB-based NPs and provide crucial insights into their rational design in disease treatment.

8 April 2026 in RSC Advances
Verified
Journal Article
Open access
PDF file
HTHarshita Tiwari
Harshita Tiwari
SSSwati Singh
Swati Singh
VKVandana Kumari
Vandana Kumari
STShikha Tripathi
Shikha Tripathi
ASAnurag Kumar Singh
Anurag Kumar Singh
Vibhav GautamVibhav Gautam
Vibhav Gautam
Fabrication and characterization of MTX-MWCNT nanoconjugate for evaluation of its cytotoxic activity, hemocompatibility, anti-angiogenic potential, molecular expression and morphological alterations through in vitro assays.